Bortezomib attenuates acute graft-vs.-host disease through interfering with host immature dendritic cells

Experimental Hematology

Volumn 39, Issue 6, 2011, Pages 710-720

  Tao, Yi ^a   Zhang, Weiwei ^a   Fang, Yuan ^a   Yang, Dan ^a   Wang, Liping ^a   Zhou, Hong ^a   Wang, Jianmin ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; I KAPPA B ALPHA; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BONE MARROW TRANSPLANTATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE SEVERITY; DRUG EFFECT; GRAFT VERSUS HOST REACTION; HOST CELL; IMMUNOSTIMULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN CELL; T LYMPHOCYTE;

ACUTE DISEASE; ANIMALS; BORONIC ACIDS; CYTOKINES; DENDRITIC CELLS; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRAZINES;

MURINAE; MUS;

EID: 79956270839     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.03.001     Document Type: Article

References (45)

1. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43:3-10.
2. Teshima T., Ordemann R., Reddy P., et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002, 8:575-581.
3. Li J.M., Waller E.K. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 2004, 10:540-551.
4. Duffner U., Lu B., Hildebrandt G.C., et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol 2003, 31:897-902.
5. Matzinger P. The danger model: a renewed sense of self. Science 2002, 296:301-305.
6. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol 2003, 21:149-161.
7. Sanchez-Sanchez N., Riol-Blanco L., de la Rosa G., et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 2004, 104:619-625.
8. Steinman R.M., Hawiger D., Nussenzweig M.C. Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711.
9. Shakhar G., Lindquist R.L., Skokos D., et al. Stable T cell-dendritic cell interactions precede the development of both tolerance and immunity in vivo. Nat Immunol 2005, 6:707-714.
10. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004, 430:257-263.
11. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature 1998, 392:245-252.
12. Chorny A., Gonzalez-Rey E., Fernandez-Martin A., Ganea D., Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 2006, 107:3787-3794.
13. MacDonald K.P., Kuns R.D., Rowe V., et al. Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD. Blood 2007, 109:5049-5057.
14. Vodanovic-Jankovic S., Hari P., Jacobs P., Komorowski R., Drobyski W.R. NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 2006, 107:827-834.
15. Ouaaz F., Arron J., Zheng Y., Choi Y., Beg A.A. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 2002, 16:257-270.
16. Yoshimura S., Bondeson J., Brennan F.M., Foxwell B.M., Feldmann M. Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol 2001, 31:1883-1893.
17. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001, 7:1419-1428.
18. Mitsiades N., Mitsiades C.S., Richardson P.G., et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
19. McBride W.H., Iwamoto K.S., Syljuasen R., Pervan M., Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 2003, 22:5755-5773.
20. Sun K., Welniak L.A., Panoskaltsis-Mortari A., et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004, 101:8120-8125.
21. Sun K., Wilkins D.E., Anver M.R., et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood 2005, 106:3293-3299.
22. Fujii S., Liu K., Smith C., Bonito A.J., Steinman R.M. The linkage of innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and CD80/86 costimulation. J Exp Med 2004, 199:1607-1618.
23. Qian C., An H., Yu Y., Liu S., Cao X. TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 2007, 109:3308-3315.
24. Gao L., Lu C., Xu C., Tao Y., Cong B., Ni X. Differential regulation of prostaglandin production mediated by corticotropin-releasing hormone receptor type 1 and type 2 in cultured human placental trophoblasts. Endocrinology 2008, 149:2866-2876.
25. Sun Y., Tawara I., Toubai T., Reddy P. Pathophysiology of acute graft-versus-host disease: recent advances. Transl Res 2007, 150:197-214.
26. Schmaltz C., Alpdogan O., Muriglan S.J., et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood 2003, 101:2440-2445.
27. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002, 277:16639-16647.
28. Chen X., Oppenheim J.J., Howard O.M. BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice. J Leukoc Biol 2005, 78:114-121.
29. Zhang Y., Shlomchik W.D., Joe G., et al. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J Immunol 2002, 169:7111-7118.
30. Zhang Y., Louboutin J.P., Zhu J., Rivera A.J., Emerson S.G. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease. J Clin Invest 2002, 109:1335-1344.
31. Cooke K.R., Hill G.R., Crawford J.M., et al. Tumor necrosis factor- alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998, 102:1882-1891.
32. Liu T., Matsuguchi T., Tsuboi N., Yajima T., Yoshikai Y. Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice. Infect Immun 2002, 70:6638-6645.
33. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
34. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004, 22:2108-2121.
35. Chen X., Murakami T., Oppenheim J.J., Howard O.M. Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking. Blood 2005, 106:2409-2416.
36. Nencioni A., Schwarzenberg K., Brauer K.M., et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 2006, 108:551-558.
37. Straube C., Wehner R., Wendisch M., et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007, 21:1464-1471.
38. Subklewe M., Sebelin-Wulf K., Beier C., et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007, 68:147-155.
39. Korngold R., Marini J.C., de Baca M.E., Murphy G.F., Giles-Komar J. Role of tumor necrosis factor-alpha in graft-versus-host disease and graft-versus-leukemia responses. Biol Blood Marrow Transplant 2003, 9:292-303.
40. van Leeuwen L., Guiffre A., Atkinson K., Rainer S.P., Sewell W.A. A two-phase pathogenesis of graft-versus-host disease in mice. Bone Marrow Transplant 2002, 29:151-158.
41. Zhang Y., Chirmule N., Gao G.P., et al. Acute cytokine response to systemic adenoviral vectors in mice is mediated by dendritic cells and macrophages. Mol Ther 2001, 3:697-707.
42. Naito Y., Handa O., Takagi T., et al. Ubiquitin-proteasome inhibitor enhances tumour necrosis factor-alpha-induced apoptosis in rat gastric epithelial cells. Aliment Pharmacol Ther 2002, 16(suppl 2):59-66.
43. Rajkumar S.V., Richardson P.G., Hideshima T., Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005, 23:630-639.
44. Nencioni A., Garuti A., Schwarzenberg K., et al. Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 2006, 36:681-689.
45. Koreth J., Stevenson K.E., Kim H.T., et al. Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood 2009, 114:3956-3959.